The global ovarian cancer diagnostics market size is expected to reach USD 2.3 billion by 2028, registering a CAGR of 6.7% over the forecast period, according to the latest report by Reports and Data. Major factors driving market revenue growth are rising prevalence of ovarian cancer and increasing awareness about the importance of early detection of ovarian cancer.
Ovarian cancer is the seventh leading cause of death and morbidity in women worldwide. It is a complicated type of cancer that often affects women over the age of 65. Various studies have established the age group of 50–79 years as the average for diagnosis. Women have a one-in-75 risk of developing ovarian cancer and a one-in-one-hundred chance of dying from it. The prevalence of the disease varies by age and race, with the latter being more prevalent in less developed countries. Ovarian cancer incidence rates in Europe increased significantly from 1982 to 2008, increasing from 4.9 to 6.1 per 100,000 females. In the U.S., ovarian cancer accounted for 81.8 percent of all cancer cases in 2012.
Ovarian cancer is most common in women between the ages of 50 and 79. It is becoming more prevalent as the world's geriatric population grows and there is a greater emphasis on early detection and treatment, which is expected to accelerate ovarian cancer diagnostic market development. Increasing government investment in raising awareness about early cancer detection as well as increasing health-care spending would also propel business growth.
Obesity appears to play a significant role in the development of ovarian cancer. Other lifestyle choices that can raise the risk include smoking, drinking, and not having children. Since ovarian cancer is not easily detectable, women who are at risk of developing the disease must undergo routine testing to identify the disease early, allowing the market to expand.
Lack of knowledge about the exact causative factors and a late diagnosis of the disease are two major factors limiting development. In order to identify key genes or biochemical pathways that could be targeted for diagnosis and treatment, a better understanding of the underlying molecular processes is critical.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/4093
The report provides a panoramic view of the market and insights that will help formulate better business decisions. In addition to that, the study helps well-established companies and players gain a deeper understanding of the market and make informed decisions. The report also discusses in detail about the key factors influencing the market growth.
Key companies operating in the market include:
- Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Johnson Johnson Services, Inc.; AstraZeneca plc; Siemens Healthcare GmbH; Quest Diagnostics Incorporated.; Thermo Fisher Scientific; Bio-Rad Technologies Inc.; and Abbott.
The report covers an extensive analysis of the key market players in the market along with their business overview, expansion plans, and strategies. The report also focuses on recent strategic alliances in the market including mergers and acquisitions, joint ventures, partnerships, agreements, corporate and government deals, product launches, and brand promotions, among others.
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/4093
The report aims to provide a better understanding of the market dynamics and the workings of the industry on a global level. To gain a deeper understanding of the industry, the global Ovarian Cancer Diagnostics market is further segmented on the basis of key geographical regions such as North America, Latin America, Europe, Asia-Pacific, and the Middle East Africa. The report also offers a country-wise analysis to provide crucial insights into market size, market growth, market revenue growth, and economic growth in each region.
On basis of product types and application offered by the Ovarian Cancer Diagnostics industry, the market is segmented into:
Cancer Type Outlook (Revenue, USD Billion; 2018 – 2028)
- Epithelial Tumour
- Germ Cell Tumour
- Stromal Cell Tumour
- Others
Diagnosis Type Outlook (Revenue, USD Billion; 2018 – 2028)
- Imaging
- Ultrasound
- CT Scan
- MRI Scan
- PET Scan
- Others
- Blood Test
- CA125
- HER2
- BRCA
- CEA
- ER PR
- KRAS Mutation
- Others
- Biopsy
- Others
End User Outlook (Revenue, USD Billion; 2018 – 2028)
- Hospital Laboratories
- Cancer Diagnostic Centers
- Research Institutes
- Others
The regional analysis covers:
- North America
- US.
- Canada
- Mexico
- Europe
- Germany
- UK.
- Italy
- France
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East Africa
- Saudi Arabia
- A.E.
- South Africa
- Rest of MEA
To know more about the report @ https://www.reportsanddata.com/report-detail/ovarian-cancer-diagnostics-market
Benefits of Ovarian Cancer Diagnostics Market Report:
- Panoramic overview of the opportunities and risks in the Ovarian Cancer Diagnostics sector
- Study of recent innovations and developments in the industry
- Comprehensive study of the growth pattern of the Ovarian Cancer Diagnostics industry
- In-depth assessment of the competitive landscape of the key players of the Ovarian Cancer Diagnostics industry
- Analysis of the Ovarian Cancer Diagnostics market drivers, constraints, and opportunities
- Assessment of technological developments and latest trends of the industry
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/4093
Thank you for reading our report. For customization or further inquiry, please get in touch with us. Our team will ensure the report is tailored according to your requirements.
Browse More Reports :
Microsurgery Market Companies
